A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

LESSONS LEARNED. The addition of the heat shock protein 27 (Hsp27)‐targeting antisense oligonucleotide, apatorsen, to a standard first‐line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer. Findings from this trial hint at the possible...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Andrew H., Murphy, Patrick B., Peyton, James D., Shipley, Dianna L., Al‐Hazzouri, Ahmed, Rodriguez, Francisco A., Womack, Mark S., Xiong, Henry Q., Waterhouse, David M., Tempero, Margaret A., Guo, Shuangli, Lane, Cassie M., Earwood, Chris, DeBusk, Laura M., Bendell, Johanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728028/
https://www.ncbi.nlm.nih.gov/pubmed/28935773
http://dx.doi.org/10.1634/theoncologist.2017-0066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728028/
https://www.ncbi.nlm.nih.gov/pubmed/28935773
http://dx.doi.org/10.1634/theoncologist.2017-0066

Ejemplares similares